Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FOLFOXIRI Alone for CRM+ Rectal Cancer
NCT03161574Phase 2Withdrawn
- Sponsor
- Guangxi Medical University
- Start
- Aug 2017
- Primary completion
- Dec 2019
- Modality
- DNA Intercalators/Alkylators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of fluorouracil, folinic acid, oxaliplatin and irinotecan in rectal cancer, sponsored by Guangxi Medical University. Primary endpoints: The rate of negative circumferential margin status at 30 days and The rate of R0 resection at 30 days. Planned start Aug 2017; status: withdrawn.
02
Drugs
fluorouracilfolinic acidoxaliplatinirinotecan
03
Conditions
rectal cancer
Beyond the preview
Go deeper on NCT03161574.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03161574.